GlassScriptPhysician profile
Sam Hawkins
NPI 1912695487
$5,799.18
in general payments reported to CMS, 2019-2025
21 companies · $3,012 in 2025
The $3,012 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $916 · 2024: $1,871 · 2025: $3,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,799.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.59 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $761.61 | 2023-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $724.82 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $608.97 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $506.40 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.41 | 2023-2025 | Caplyta |
| Almatica Pharma LLC | $291.72 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $231.82 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $227.17 | 2023-2025 | Trintellix |
| Indivior INC. | $134.92 | 2024-2025 | Sublocade |
| Corium, LLC | $131.86 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $126.05 | 2024-2025 | Auvelity |
| Sage Therapeutics, LLC | $116.49 | 2024-2025 | Zurzuvae |
| Braeburn INC. | $112.29 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $107.97 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $101.41 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $87.54 | 2023-2025 | Austedo Xr, Uzedy |
| Lundbeck LLC | $70.90 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $36.04 | 2024 | |
| Neos Therapeutics, LP | $23.71 | 2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $22.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Hawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.